Company Overview of Premune AB
Premune AB, an animal health company, develops treatments for allergies, inflammatory bowel diseases, and other immune disorders in pets worldwide. Its developments are targeting problem areas in veterinary medicine. The company was founded in 2009 and is based in Stockholm, Sweden.
Kungsgatan 3 vån 4
Stockholm, 111 43
Founded in 2009
Key Executives for Premune AB
Co-Founder and Chief Executive Officer
Head of Licensing & Regulatory Affairs and Director
Head of Clinical Development
Compensation as of Fiscal Year 2014.
Premune AB Key Developments
Premune AB Presents at 8th Annual OneMedForum 2015, Jan-12-2015 03:15 PM
Dec 18 14
Premune AB Presents at 8th Annual OneMedForum 2015, Jan-12-2015 03:15 PM. Venue: San Francisco Marriott Marquis, Parc 55 Wyndham, Union Square, San Francisco, California, United States. Speakers: Viktor Karlsson, Co-Founder and Chief Executive Officer.
Premune Appoints Carl K. Johnson as Chief Medical Officer
Aug 20 14
Premune announced the appointment of Dr. Carl K. Johnson, D.V.M. as Chief Medical Officer. Johnson, who will be based in Premune's New York office and report directly to CEO Viktor Karlsson, will be responsible for Premune's global product development initiatives. Johnson is the most recent senior-level hire since the Company announced the establishment of its U.S. office on April 15, 2014. Johnson joins Premune with more than 25 years of experience in animal health. Most recently, he was Global Head of Project and Portfolio Management at Merial, where his team developed new pharmaceutical and biological products including, NexGard, which is used for the treatment of fleas and ticks, and Broadline.
Premune Appoints Eileen Daloia as Head of Regulatory Affairs
May 29 14
Premune announced the appointment of Eileen Daloia as Head of Regulatory Affairs. Ms. Daloia, who will be based in Premune's New York office and report directly to CEO Viktor Karlsson, will oversee all regulatory initiatives associated with the approval of the company's veterinary treatment product candidates. Ms. Daloia is the third senior-level hire since the company announced its U.S. subsidiary on April 15, 2014, joining Michio Soga, CFO and Mickey McDermott, Global Head of Marketing. Most recently, she was Director, Regulatory Affairs -- US and Canadian Divisions for Virbac Animal Health, where she contributed to a number of New Animal Drug Application ("NADA") and Minor Use Minor Species ("MUMS") approvals during her three years in the position.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|